Gallium Ga 68 Pentixafor PET/CT in Diagnosing Patients with Neuroendocrine Tumors

Inclusion Criteria

• Histological diagnosis of NET
• Had a prior 68Ga DOTATATE PET/CT scan and a CT or magnetic resonance imaging (MRI) with or without contrast performed within 3 months before signing the consent, without interval treatment other than a somatostatin analog
• CT or MRI must demonstrate at least one lesion (primary or metastatic) present 1.5 cm or larger in any dimension on cross-sectional imaging (CT or MRI) obtained within 3 months of study enrollment
• Results of CXCR4 immunohistochemistry or slides from biopsy of primary tumor or metastatic lesions available for study analysis
• Participation in the Iowa Neuroendocrine Tumor Registry
• Planned administration of any NET therapy between scan 1 and 2, except for short acting octreotide

Exclusion Criteria

• Uncontrolled intercurrent illness including, but not limited to ongoing or active infection requiring hospitalization, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
• Physical limitation that would limit compliance with the study requirements
• Pregnant or lactating women; should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately; a negative pregnancy test will be required for all female subjects with child bearing potential